XiaoMi-AI文件搜索系统
World File Search SystemImmunos
Immunos Therapeutics AG筹集了1100万美元，并进一步增强
2024年9月17日 - 一家生物制药公司Immunos Therapeutics AG利用其独特的免疫系统调节基于HLA的技术平台来开发第一类治疗癌症治疗癌症和自身免疫性疾病，今天宣布关闭C系列C融资1100万美元的C系列融资。这一轮由现有投资者GIMV，辉瑞公司（Pfizer Ventures），任务Biocapital，Biomed Partners和新投资者Double Double Point Ventures以及其他现有投资者的支持。与巡回赛结合，Mission Biocapital的总合伙人Steve Tregay加入了公司的董事会。C系列的收益将用于进一步资助Immunos铅计划IOS-1002的持续临床试验，以完成IA期剂量升级临床试验作为单一疗法，并与MSD's（Merck＆Co.，Inc.，Inc.，Inc.，Rahway，NJ，NJ，USA，USA）抗PD-1治疗pspremtruda®（pembrolizbab）。ios-1002是一种新型的多功能免疫疗法，用于治疗晚期实体瘤，同时靶向几个免疫检查点。It is based on a naturally occurring human leukocyte antigen (HLA) targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 and designed to activate both innate and adaptive immune cells to modulate the tumor microenvironment, potentially also enhancing the ebectiveness of existing IO treatments such as KEYTRUDA.“我们很高兴与现有和新投资者结束这一重要的融资，” Immunos Therapeutics董事会执行董事长Reinhard Ambros说。资金使我们能够继续进行iOS-1002作为单一疗法并与KeyTruda结合使用。“提升强调了我们对良好自由主义铅计划的高度兴趣，并可能具有高度相关的治疗选择。ios-1002是全球基于HLA的最先进的计划，涉及这些相关目标，并采用了这种新颖的多功能免疫疗法方法。”
Immunos Therapeutics扩展了iOS的I期临床试验...
Schlieren (Zurich Area), Switzerland – July 24, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company using its HLA-based technology platform to develop first-in-class and innovative therapeutics for the treatment of cancer and autoimmune diseases, today announced the expansion of its ongoing Phase I clinical trial of IOS-1002 in combination with MSD (Merck & Co., Inc.,美国新泽西州拉威（Rahway）的抗PD-1疗法，KeyTruda®（Pembrolizumab）用于治疗晚期实体瘤。这是旨在评估安全性，确定最佳剂量并评估iOS-1002的抗肿瘤活性并与KeyTruda结合使用KeyTruda（一种已建立的免疫检查点抑制剂）时，旨在评估安全性，确定最佳剂量并评估iOS-1002的抗肿瘤活性，并评估iOS-1002的抗肿瘤活性。“我们很高兴开设正在进行的I期临床试验的新部门，并将iOS-1002与世界领先的PD1抑制剂KeyTruda结合在一起，” Immunos Therapeutics委员会首席执行官兼执行董事长Reinhard Ambros博士说。“ ios-1002有可能增强KeyTruda的抗肿瘤活性，为晚期实体瘤患者提供了有希望的新治疗选择。这项试验是我们开发创新疗法来利用免疫系统对抗癌症的创新疗法的重要里程碑。” “ iOS-1002与KeyTruda的组合代表了一种创新的癌症治疗方法，通过靶向多种抑制性检查点受体来利用这两种疗法的优势，” Peter MacCallum Cancer Center of Melbourne Center of Melbourne Center at Australia澳大利亚澳大利亚澳大利亚澳大利亚澳大利亚，研究员Stephen Luen博士说有关更多信息，请访问www.immunostherapeutics.com。“我们期待评估治疗选择有限的晚期癌症患者的最佳治疗方法。” iOS-1002是一种新型的多功能免疫疗法，用于治疗晚期实体瘤，同时靶向多个免疫检查点。它基于靶向LILRB1（ILT2），LILRB2（ILT4）和KIR3DL1的天然存在的人类白细胞抗原（HLA）。旨在激活先天和适应性免疫细胞，它调节肿瘤微环境，有可能增强现有处理（如KeyTruda）的有效性。通过结合这两种疗法，Immunos Therapeutics旨在改善患者预后，并扩大与晚期实体瘤作斗争的个体的治疗选择。Immunos Therapeutics致力于促进iOS-1002的临床发展，并探索其改善癌症患者生活的潜力。KeyTruda®是Merck Sharp＆Dohme LLC的注册商标，这是美国新泽西州Rahway的子公司Merck＆Dohme LLC。
脾边缘区B细胞通过塑造细胞因子模式和细胞介导的免疫
Chen-Yu Tsai，1 Myo OO，1 Jih Hou Peh，2 Benjamin C.M.Yeo，3 Ariel Aptekmann，1 Bernett Lee，4,5,6 Joe J.J. Liu, 2 Wen-Shan Tsao, 1 Thomas Dick, 1,7 Katja Fink, 4 and Martin Gengenbacher 1,7,8, * 1 Center for Discovery and Innovation (CDI), Hackensack Meridian Health, 111 Ideation Way, Nutley, NJ 07110, USA 2 Biosafety Level 3 Core, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Level 15, Centre for Translational Medicine (MD6), NUS, 14 Medical Drive, Singapore 117599, Singapore 3 Infectious Diseases Translational Research Programme and Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Level 2, Blk MD4, 5 Science Drive 2, Singapore 117545, Singapore 4 Singapore Immunology Network (SIgN), Agency for Science Technology and Research, Biopolis, 8A Biomedical Grove, Level 3 & 4, Immunos Building, Singapore 138648, Singapore 5 Centre for Biomedical Informatics, Lee Kong Chian School of Medicine, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798, Singapore 6 A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research, 8A Biomedical Grove #05-13, Immunos,新加坡138648，新加坡7 Hackensack Meridian医学院，Nutley，NJ 07110，美国8铅联系 *通信 *通信：martin.gengenbacher@gmail@gmail.comYeo，3 Ariel Aptekmann，1 Bernett Lee，4,5,6 Joe J.J. Liu, 2 Wen-Shan Tsao, 1 Thomas Dick, 1,7 Katja Fink, 4 and Martin Gengenbacher 1,7,8, * 1 Center for Discovery and Innovation (CDI), Hackensack Meridian Health, 111 Ideation Way, Nutley, NJ 07110, USA 2 Biosafety Level 3 Core, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Level 15, Centre for Translational Medicine (MD6), NUS, 14 Medical Drive, Singapore 117599, Singapore 3 Infectious Diseases Translational Research Programme and Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Level 2, Blk MD4, 5 Science Drive 2, Singapore 117545, Singapore 4 Singapore Immunology Network (SIgN), Agency for Science Technology and Research, Biopolis, 8A Biomedical Grove, Level 3 & 4, Immunos Building, Singapore 138648, Singapore 5 Centre for Biomedical Informatics, Lee Kong Chian School of Medicine, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798, Singapore 6 A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research, 8A Biomedical Grove #05-13, Immunos,新加坡138648，新加坡7 Hackensack Meridian医学院，Nutley，NJ 07110，美国8铅联系 *通信 *通信：martin.gengenbacher@gmail@gmail.com